These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 17997283

  • 1. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections.
    Ball P.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S113-7. PubMed ID: 17997283
    [Abstract] [Full Text] [Related]

  • 2. Introduction: historical perspective and development of amoxicillin/clavulanate.
    Geddes AM, Klugman KP, Rolinson GN.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S109-12. PubMed ID: 17900874
    [Abstract] [Full Text] [Related]

  • 3. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 4. Amoxicillin/clavulanate therapy of respiratory tract infections: a microbiologic perspective.
    Cunha BA.
    Clin Ther; 1992 Jan; 14(3):418-25. PubMed ID: 1638583
    [Abstract] [Full Text] [Related]

  • 5. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB, Pal P, Jain S, Kulkarni KP.
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [Abstract] [Full Text] [Related]

  • 6. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.
    Arch Intern Med; 2008 Sep 22; 168(17):1897-902. PubMed ID: 18809817
    [Abstract] [Full Text] [Related]

  • 7. Development of a twice daily dosing regimen of amoxicillin/clavulanate.
    Bax R.
    Int J Antimicrob Agents; 2007 Dec 22; 30 Suppl 2():S118-21. PubMed ID: 17983732
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conclusions: the future of antimicrobial therapy - Augmentin and beyond.
    Ball P.
    Int J Antimicrob Agents; 2007 Dec 22; 30 Suppl 2():S139-41. PubMed ID: 18029150
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
    File TM, Benninger MS, Jacobs MR.
    Clin Lab Med; 2004 Jun 22; 24(2):531-51. PubMed ID: 15177852
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb 22; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 15. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS, Jacobs MR, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 Mar 22; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [Abstract] [Full Text] [Related]

  • 16. [Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
    Barcelona L, Marín M, Stamboulian D.
    Medicina (B Aires); 2008 Mar 22; 68(1):65-74. PubMed ID: 18416324
    [Abstract] [Full Text] [Related]

  • 17. Augmentin treatment of bacterial infections in hospitalised patients.
    Ellis-Pegler RB, Lang SD, Downey DJ, Anderson MP.
    N Z Med J; 1982 Aug 11; 95(713):542-5. PubMed ID: 6752781
    [Abstract] [Full Text] [Related]

  • 18. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR, Nichol KA, Nicolle LE, DeCorby M, McCracken M, Mulvey MR, Zhanel GG.
    J Antimicrob Chemother; 2006 Jun 11; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Lower urinary tract infections: bacterial epidemiology and recommendations].
    Bergogne-Bérézin E.
    Prog Urol; 2008 Feb 11; 18(1 Suppl FMC):F11-4. PubMed ID: 18773847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.